Andrew Guggenhime, PRESIDENT AND CFO at Vaxcyte, Inc. (PCVX), sold 84,000 shares at $116.19 ($9.7M) on 2024-10-18, disclosed to the SEC on 2024-10-22.
Scheduled sale ($9.7M) by PRESIDENT AND CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $115.26 | 36,114 | $4.2M | 42.9% |
| 2 | $115.26 | 36,114 | $4.2M | 42.9% |
| 3 | $116.19 | 5,886 | $684K | 7.1% |
| 4 | $116.19 | 5,886 | $684K | 7.1% |
| Total | $115.39 avg | 84,000 | $9.7M | 100% |
| Filing → |
| PCVX | SELL | 2026-06-18 | $530K | — | Filing → |
| PCVX | SELL | 2025-02-19 | $1.3M | — | Filing → |
| PCVX | SELL | 2025-01-22 | $1.4M | — | Filing → |